Now showing items 1-7 of 7

    • Endothelial Expression of Endothelin Receptor A in the Systemic Capillary Leak Syndrome. 

      Sek, AC; Xie, Z.; Terai, K.; Long, LM; Nelson, C.; Dudek, AZ; Druey, KM (Public Library of Science, 2015-07-15)
      Idiopathic systemic capillary leak syndrome (SCLS) is a rare and potentially fatal vascular disorder characterized by reversible bouts of hypotension and edema resulting from fluid and solute escape into soft tissues. ...
    • Iron deficiency modifies gene expression variation induced by augmented hypoxia sensing 

      Zhang, Xu; Zhang, Wei; Ma, Shwu-Fan; Miasniakova, Galina; Sergueeva, Adelina; Ammosova, Tatiana; Xu, Min; Nekhai, Sergei; Nourai, Mehdi; Wade, Michael S.; Prchal, Josef T.; Garcia, Joe G. N.; Machado, Roberto F.; Gordeuk, Victor R. (Elsevier Inc., 2014-01)
      In congenital Chuvash polycythemia (CP), VHLR200W homozygosity leads to elevated hypoxia inducible factor (HIF) levels at normoxia. CP is often treated by phlebotomy resulting in iron deficiency, permitting us to examine ...
    • Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue, PSA146-154 

      Perambakam, Supriya; Xie, Hui; Edassery, Seby; Peace, David J. (Hindawi Publishing Corporation, 2010)
      Twenty eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate specific antigen, PSA146-154, between July 2002 to September ...
    • A multicolor panel of TALE-KRAB based transcriptional repressor vectors enabling knockdown of multiple gene targets 

      Zhang, Z.; Wu, E.; Qian, Z.; Wu, W.S. (Nature Publishing Group, 2014-12-05)
      Stable and efficient knockdown of multiple gene targets is highly desirable for dissection of molecular pathways. Because it allows sequence-specific DNA binding, transcription activator-like effector (TALE) offers a new ...
    • Outcome after reduced chemotherapy for intermediate-risk neuroblastoma 

      Baker, David L.; Schmidt, Mary L.; Cohn, Susan L.; Maris, John M.; London, Wendy B.; Buxton, Allen; Stram, Daniel; Castleberry, Robert P.; Shimada, Hiroyuki; Sandler, Anthony; Shamberger, Robert C.; Look, Thomas; Reynolds, Patrick; Seeger, Robert C.; Matthay, Katherine (Massachusetts Medical Society, 2010-09-30)
      Background The survival rate among patients with intermediate-risk neuroblastoma who receivedose-intensive chemotherapy is excellent, but the survival rate among patients whoreceive reduced doses of chemotherapy for shorter ...
    • Pharmacogenomics of chemotherapeutic susceptibility and toxicity 

      Zhang, Wei; Moen, Erika L.; Godley, Lucy A.; Dolan, M. Eileen (BioMed Central, 2012-11)
      ABSTRACT: The goal of personalized medicine is to tailor a patient's treatment strategy on the basis of his or her unique genetic make-up. The field of oncology is beginning to incorporate many of the strategies of ...
    • Targeting the HGF-cMET Axis in Hepatocellular Carcinoma 

      Venepalli, Neeta K.; Goff, Laura (Hindawi Publishing Corporation, 2013-03)
      Under normal physiological conditions, the hepatocyte growth factor (HGF) and its receptor, the MET transmembrane tyrosine kinase (cMET), are involved in embryogenesis, morphogenesis, and wound healing. The HGF-cMET axis ...